Can Motilium Prolong the QT Interval?
Yes, domperidone (Motilium) is recognized as a QT-prolonging antiemetic that can cause torsades de pointes, though the risk occurs less frequently than with antiarrhythmic drugs.
Guideline Classification of Domperidone
The ACC/AHA/ESC guidelines explicitly list domperidone among antiemetics with "less frequent" QT-prolonging potential (compared to antiarrhythmic drugs that cause QT prolongation in >1% of patients). 1 This classification places domperidone in the same risk category as other recognized QT-prolonging agents including cisapride, certain anti-infectives, and antipsychotics. 1
Mechanism and Clinical Significance
Domperidone blocks the rapidly activating delayed rectifier potassium current (IKr), the primary mechanism by which most QT-prolonging drugs delay cardiac repolarization. 2
The drug can expose subclinical congenital long QT syndrome and interacts synergistically with other QT-prolonging medications or electrolyte abnormalities. 1
When QTc reaches ≥500 ms, domperidone must be discontinued immediately and continuous cardiac telemetry initiated, as this threshold markedly increases torsades de pointes risk. 2, 3
Evidence from Clinical Studies
Recent research provides nuanced risk stratification:
A 2019 single-center study of 246 gastroparesis patients receiving domperidone 30-80 mg daily found that only 6.1% developed clinically important QTc prolongation, with no patient reaching the critical threshold of QTc >500 ms. 4 However, 24.7% showed QTc increases ≥20 ms from baseline. 4
A 2021 observational study demonstrated that the combination of domperidone with ondansetron and olanzapine produced statistically significant QTc prolongation on Day 1 of treatment, particularly in females. 5 Two female patients exceeded QTc 500 ms (using Bazett correction). 5
Pharmacovigilance data from France (2004-2013) confirmed a 2-fold increased reporting odds ratio for cardiac adverse events (QT prolongation, syncope, sudden death, ventricular arrhythmias) associated with domperidone. 6
A 2022 thorough QT study in healthy Chinese volunteers showed that domperidone 10-20 mg three times daily produced QTcF increases of only 1.3-2.7 ms, with upper confidence limits remaining below the regulatory threshold of 10 ms. 7
A 2026 phase 1 study of CIN-102 (deuterated domperidone) demonstrated no clinically meaningful QT prolongation at therapeutic and supratherapeutic exposures up to 6 times steady-state concentrations. 8
Risk Factors That Amplify Domperidone's Cardiac Effects
The following conditions substantially increase torsades de pointes risk when domperidone is prescribed: 1, 9, 1, 9
- Female sex (consistently identified as the strongest demographic risk factor)
- Hypokalemia and hypomagnesemia (the most common reversible contributors)
- Bradycardia or recent conversion from atrial fibrillation
- Congestive heart failure or left ventricular hypertrophy
- Baseline QT prolongation or congenital long QT syndrome
- Concomitant use of other QT-prolonging drugs (macrolides, fluoroquinolones, antipsychotics, antidepressants)
- Drug interactions that inhibit domperidone metabolism
Safer Antiemetic Alternatives When QTc ≥500 ms
Domperidone is absolutely contraindicated when baseline QTc ≥500 ms. 2, 3 Substitute with:
- Aprepitant (NK₁-receptor antagonist) – does not prolong QT and is the preferred alternative. 3
- Dexamethasone – carries no QT risk and is explicitly recommended as a substitute. 3
- Olanzapine – has negligible QT-prolongation potential at antiemetic doses. 3
Monitoring Requirements
When domperidone cannot be avoided:
- Obtain baseline ECG with QTc measurement before initiating therapy, especially when other QT-prolonging drugs are prescribed concurrently. 9, 2
- Correct electrolytes before starting domperidone: potassium >4.5 mmol/L, magnesium >2.0 mg/dL, normalize calcium. 2, 3
- Repeat ECG at 2-6 months, 6-12 months, and annually during chronic therapy. 4
- Discontinue immediately if QTc exceeds 500 ms or increases >60-70 ms from baseline. 2, 3
Critical Clinical Pitfalls
Do not combine domperidone with ondansetron or other QT-prolonging antiemetics without baseline ECG and close monitoring, as the combination significantly amplifies QT prolongation risk. 5
Do not overlook electrolyte abnormalities in patients on diuretics, as hypokalemia and hypomagnesemia are the most common contributors to drug-induced long QT syndrome. 1, 2
Do not assume domperidone is safe in pediatric patients; pathological QTc intervals have been documented in infants, warranting individual assessment and routine ECG monitoring. 10
Always check crediblemeds.org before adding any medication to a patient receiving domperidone, as drug-drug interactions can dramatically elevate QT risk. 11, 2